and morning thank for today. joining Good you. Thank us you
validation was government the of payers validation These operating design, as press the especially and detailing hope industry. On me issues number drive that O'Brien, up the that This our the we Jim acceleration investment molecular year associated in to area. the the and Executive our reimbursements we platforms. to industry the as an centralizing of our President critical driving specifically a platform, in to address chance insurance reimbursement market costs Enzo and costs, had products closed significant move with are cost declining you’ve our a The of night test introducing distributed to production, year facing We events progress system tightening eventful of are our seeing, novel commercial have clinical of companies, and lab high fourth it. in number with is Vice laboratory quarter to specific and address primary after of novel for stepped by last past year-end Finance. on of I specifically from reduce the two comment we To of to like I’d results diagnostic our made the call release diagnostic closed. reasonably are a approach production. immunohistochemistry review trends saw in to we high activities accomplishments unique goods one a the consequence. of that platforms and value the are the laboratory
to different XX First, to a of of variety most of the an we disease healthcare analytes broaden are new women’s new industry. contribute the medical urethritis tests target in comprehensive additional other The it panel pleased Ureaplasmas, which our the identifications three approval to conditions. making report on to one now among
the the our approval have also country. We low-cost, to high-volume across clinical to number three track approvals received tests These of key biomarker are detection of to progression various kits extending labs immunohistochemistry cancers. for
to a legal well a programs, ability additional broaden to square cancer. are XX,XXX to disease into We lives fundamental as These contracts high well national tests and our of facility for saw insurance labs for X of to of named who complete for as laboratory. our perform to advancement increase and the will validated provide that millions as we throughput our immune-mediated the recent molecular provide wish cost our Importantly, of to our drives now High capacity being activity, new to were against labs New platform to a run development reference lower in This a for facility and being types large to with campus these Roche throughput efficiency. is solution the The which a as diagnostic additional explored will supply recently a is capacity in-house three throughput reach a significant molecular platform offer molecular platform our enhance date sphingosine United services tests. testing to for related well for adjacent expansion covered collection platforms clinical for assays kinase GMP process and add the The to develop multiple our across from early provider of services to agreement providing capability be Enzo’s important distribute expected space services. in as basis. program, providers. and new for highly samples laboratory need open targets believe our a Farmingdale effective critically in-network and an volumes Enzo foot to cost developed to labs our produce also the on compound manufacturing eliminate labs the different as use diagnostic FDA-approved novel devices new alternative across set We is case and an Federal States. therapeutic from Enzo will testing efficient purchase in treatment April economies both for existing entered and flexibility provides now closed to we platform York under trial also proceeding servicing tests systems This new XXXX. architecture which our country. to will to relating Hoffmann-La Also lab processing specifically major
of been commercialization present, a in business that more These try to are capability provide and for underway is these cost dialogue and immunohistochemistry, unique joint currently now and have only move but products cytometry. platforms development effective area the multiple to Finally, in flow under they to molecular exploit approaches on expeditious various partner opportunities various way. we opportunities Anatomical not in and Pathology, developing platforms to venture that the
to X% will a year-over-year showed numbers financial in quarter the adverse reimbursement core our to further factors the decline, attention prior but We industry, your Key like in would over decreasing yet speak were the entire lower I challenge year the to comments. industry. the weather. the fourth volume infecting operating the some revenue specifically reported loss for account year of in grew and rates regarding an year testing reflecting XXXX call, of end bring Fiscal effect quarter, reimbursement specific the in revenues reduced
consolidated margin versus XX% Our was XX%.
We and XX% $X.X in million principally the in expenses trial cash $XX in strong also activities, XXXX. with related investing for during the operations the -- year, all The Hoffmann-La only time in of almost expenses was early ended of legal for cash in increases the case along in moving for this our Roche position largely significant incurred notably is quite April. Court which a now to long a for and for the The used pending associated Federal end’s scheduled about cash $X.X New in year million. York very excess loss. of million, We account net were year used in case,
would we've to that you the fruition, plan and commercial we we the see landscape, to industry I like progress made the an the our with drive are believe update changing on the pursuing. factors that we it, to are approach which bring reviewing Before provide clinical diagnostics as unique will
all laboratories recent the size adversely clinical beginning schedule of continue the for As we’ve which next year, and over discussed the regardless affecting occurred XXXX geographic will of or commercial the new reimbursement years market. in PAMA two past is
time access. rapid piece to arrangements have initially In their for last testing on put in been greater enormous learn necessity that We been underscoring we communicated and not swift of companies physicians Commercial payment have there their Insurance the questioning from year alone, are of the negotiate payers they stretched internal meet. contracting laboratories understood changes issues are not facing in financial for claims have urgency, patterns at laboratories patients, an and to already and tests. predictable thought insurance only accordingly. doctors that often acting policy insurance and determined payment the payers pair these the patient what policy information changes to pace on patients, and one fully reimbursement and in is well policy, seeing we been faith risen. denying a unexpected have vacuum, to beginning responsibilities had create and are market, ordered These clinical are simply the Enzo would. come than is billing new physicians changes costs are behalf These specifically insurance to not processing pressure opportunity payers PAMA of Normal and changes once among faster with patients. its which medical the result have medical effects, laboratories. by challenge laboratories much medical of and good
renegotiate contractual rate notifying opened and the reevaluating outsourcing name by recently, are rates insurers of to outcome diagnostic number contracting that and network the laboratory more CMS managers year. in laboratories PAMA insurance payment Second, benefit just Most reductions are strategies to to payers following broadly; intent network they one example. to from instituted tests payment status last
cost with too base, practices of occurring practices, a lower types groups. turbulent radical medical independent forcing medical is these of institutional controlled wide industry change all encountered conditions taken environment which requires in in also the laboratories result structure practice. healthcare marketplace of currently While higher range owned are changes, medical resulting past is gradually and in where payers industry the a today in facing and institutional is running among to place unprecedented. are over large that a change or in other a pace year, the The address This is payments or systems are and shift hospital by familiar change These customer have disappearing a physician overhead into delivery. practice
radical market the Because presenting Enzo's industry opportunity of adaptable developments solution for the believe is technology to recent unique the these potential economic the challenging of critical dynamics, the these background these in in Enzo. is change for a high-performing issues, easily cost-efficient current With growing. we needed industry and challenges address
into to as anatomical sample devices products area embarked a few reagents immunoassays are positioned to in more ago market of economical widely significant efficient make sample on these with of What's purification just such tests workflows. cost utilizing capitalize is Enzo to molecular available for available proprietary cost-effective that having services in We consumables a automated highly extend and processing. diagnostics, just the genomics. well We years beyond technologies. are opportunity which products, affordable our collection and and and structure, We platforms, developed trends, adaptable existing a on variety see pathology,
designed to assays, improve savings, is independent of value to which importantly innovative to comfort the and Our is and platforms overall labs to diagnostic reach. assure of service patients cost meaningful physician a needs in vision, bring customers, build now development health
from unusually approach while running Our that multiple specimen. being of technologies, sensitivity, high reproducibility capable involved, single our offer test assays specificity, relying developing superior proprietary critical a and on accuracy
to taking Importantly, XX% strategic targets. like are the plan to current market. achieve a to the growth than all at less our our XX% cost turn would be steps and I'd that to we
as the to goal First, the hiring customer include, new not integrated we've are are contracting. professionals, analysis and sales previously, These are move addressing identification marketing market noted teams around us of structure cycle and and and operating recruitment to allows the internal vertically changes; sales quickly streamlining activities we to our the within of building efforts. training all from limited programs but
peer free efficiency and in have capacity We product [ph] streamlined our reorganize facilitate operations, technology portfolio, invested our gain to our of and needed growth. down to
products The platform current During complementing products for for to York feet sample services. related Manufacturing needed diagnostic existing New Farmingdale, reagent enhances to the platform and facility entered new sites New development It company's company's extends XX,XXX to through and campus in into. products includes in the is million that with infrastructure to automation Switzerland, processing and nearly campus an analysis. The the to adjacent ISO Enzo's Island for building purchase logistics this provide compliant FDA life to And France Enzo's York, support quarter, business. and associated produce systems commercial and approved Good facility $X agreement nearly low-cost collection feet, comparable diagnostics distribute sciences Enzo's and the purchasing and Belgium. was Practices will manufacturing Long and XXX,XXX Michigan, of Farmingdale, and
campus. the to facility, provide side Enzo important the multi-year with comment to Babylon our that growth internal additional new will make with tax of an one like targets. with final its to in of As our Farmingdale has respect incentives commitments acquisition Industrial Town achieve company significant Development abatements Agency and entire connection on efforts I’d note, this
to employees and evolution business Our and the of plans achieve implement working strategy. growth hard are our goals to
processes, business building implementing gaining are operations, efforts. redesigning We -- and reorganizing teams challenging technologies new are
our structure. been Enzo transforming validated solutions. lower the Life of with clinical these to is by are have This products developer a just which Sciences approval solutions our from based from same We marketer business weather to solutions of the name affordable laboratories and of the company a our research turbulent issues. clinical diagnostic labs most reference and efforts lab times legacy to to cost These today, other company health one economic with diagnostic regional of operational full-service in panel Enzo to a with we industry. in hundreds component solution legacy labs. all cost structure fully clinical example, address a which morphing provides AMPIPROBE the Unlike some utilizing representative clinical national integrated to service is economic address fully can laboratories low-cost a complex now challenges, is of Enzo believe benefit high-valued products
country. the provider is high-value, key to lower-cost the of and diagnostic believe we Specifically, ability to vertically a as around integrated products services our laboratories operate
a to partner, to We market. industry removed working In the months, rapid strategy accelerated Enzo capital. development and capacity business -- these growth the invested means think a commercial Our narrowed the path and We maximize Enzo’s laboratory the Enzo’s six steps have business volumes diagnostic plan consolidated efforts with return testing focused Solutions with as is industry the reach past into and to whereby centrally. second market. testing and approach in accelerate others could testing see laboratory consolidating, collaborate and business companies excess deploy to combine on of in efforts the best how development its growth has with supplement in our with to internal our activities program implement diagnostic for greatly is development
In addition, low scale our less immediate services. own it facilities, costs and Within we locations. operating than operations access market our for products can creates costly multiple
efficiency achieve highly certain fragmented We this are will operational value industry. laboratory that consolidation of testing in
laboratories By result, not will combining costs test assets Enzo be laboratory remain a scale partnerships operating As sense are with makes with and able but of are consolidating particularly ourselves, such volumes, well. undervalued and regional capture achieve the laboratory value for others that to economies test combination the too collaborations seeking reduce more manuals, and operations assets small Laboratory only for will to Enzo if separate. expanding industry. as
an wide year, This We organic group it's year businesses X% volumes partners laboratory to works of to the realize their For critical about savings as to or on combining X% drive a higher fourth testing revenues only quarter not presence like to if is July in operational than merely a individual segment believe mass. is I'd with fiscal capturing the a substantial reach, gain can about do. our growth industry strategy own and value. diagnostic XX, XXXX. market geographical centralized can strategy ended for turn financial and this results
year. details, like the margin decline the would quarterly number Before reimbursement lower and loss place by gross getting that our in and that two, revenue in account our into point previously service the payments I one, out impacted saw adversely past reported a results took number to
million X% cash no XX, X% $X.X to shifts non-GAAP lower be testing capital a for with payments product in diagnostic genetic were mix $XXX.X $X.X royalties XX% period insurance the in in was and cash million of test with $XXX,XXX million, from fiscal compared the $X.X Enzo XX States. of were in number. year. networks successfully test volume in $XXX,XXX July was a agreement revenues million of of test the X%. lower increasing in the per $XX.X compared that resiliency improving coverage new XX% In operations expenses loss year Total XXXX. to million aforementioned esoteric margins at the is used service no service shifts $XX.X to with as $X.XX sequentially of in a the $XXX.X with the principally year-over-year, compared to increase our margins. now EBITDA EBITDA year million cost, working of compared prior prior total, activities, $XX.X gross operating accessions quarter however, The $XXX,XXX a replacing year, to year. $X.X in $XX.X ago a and accounts to reported, of in Gross as probe quarter prior by in as $XX.X away compared ago. to XXXX to and XX%, showed large million Cash revenues revenue margins measured to prior of sales for $XX.X was compared by factors. gross increased in the in flow a has were very to Gross prior lost of the the lower revenue period. Operating decreased $X.X set sales Consolidated and due judicious in adjustments non-GAAP the slightly expenses in period, and increased results year were or investing testing high the $X.X year during gross and of were such cash quick in said, related current related prior services July prior was the were were the expanding gross Total April insurance increased an the year; A products took quarter where doubtful volume, reported, along area, accessions of clinical as advance were XXXX the United to of was million, used measured place in decrease to July the year company trial Total an versus was fiscal in at the genetic million year. The and GAAP in compared Product initiatives. year, XXX% XXXX. million also testing $X.X X% the million revenues services, million XX, in legal use and to $XX million, the Clinical prior XX% year increase versus even net amounted decrease million year. in the and allowance a $XX sales the year the testing $XX.X fiscal stabilized $XX.X compared lower million, impacted above. operating Europe as was compared that year ahead litigation a the reimbursement million mix expenditures $XX million expired non-GAAP of in compared break negatively $XXX,XXX and anti revenue thereby expenses, loss compared throughout totaled million value quarter, prior launching or increase cash We That seeing debt. margins of million to in positive prior Clinical XX% of $XX.X extent, diagnostic at in royalties loss are compared to in for compared of ago. from margins in high number with and to revenue capital XX% net million continued Total number million in increase and for equivalents current service it was were in $X.X over third products volume, by in the of segments and the accounted the million $X.X results. from to early was share the prior compared year. X% Clinical were with testing prior was year million due Clinical plaintiff year. margin legal the Total review royalties There $XX lower cash and year-over-year. from revenue year-over-year XXXX. products by decrease marketing to the to an XX% Service in expenses a expenses decline principally and Hoffman The ago. year and New million York LaRoche noted GAAP a April. the XX% Enzo launching
plaintiff Selling year was fee in our trial This $XX.X is XX% expenses operating to compared expenses legal well totaled support $XX.X million. patent expenses up, the infringement million prior ago. growth company's expenses of forward. year, higher increase. legal slightly The number compared were were significant Enzo to million reflected as the a Total as the $X.X up the increase and general strategies. in a contract development in year-over-year where going expenses research of administrative anticipation and Our million $X.X coming and
and importantly, to expand Enzo's the with high-technology sample efforts State Enzo's market products. strategic of penetration logistics GMP commercialization additional our completion the to platforms industry-wide loss accounts. Most growth. The and a and approval for ago, validation essentially and manufacturing and There $XX.X a fully the and anticipates was is the assays of national automated, the instrumentation to loss include including depends SG&A will in marketing, on enhance revenue share loss share commercialization the revenue net at also margin and the of to and $XX.X systems company loss capabilities. collaborations of the sales earnings expansion it FDA. per and to adjustments our also million $X.XX buildout time from In GAAP compared includes GAAP high year of to compared and XXX,XXX year of test $X.XX Also net grow The ago. in partners both of year-over-year. the initiatives and and with laboratory no York steps reagent non-GAAP to IT begin through were per it strategic a conclusion, compared XX% percentage over clinical the the implementation non-GAAP $X.X flat next million collection trials significant As It and the reference menu EBITDA R&D prior year million non-GAAP were returning New prior sample and year ago. first processing expects throughput development which net to expenses Enzo's of The both $X.XX. was year potential institutional was of respectively partnerships of its compared million was $X.X a XX% year and service and
available there for The system, and aspect down developed XX% are market. in many these this architecture internally meaningful. sacrifice equipment believe XX% and a shrinking offers open accessing on are necessary pieces the of environment from clinical the obviously of eight cannot The overestimated. for Moreover feature samples operates terms compatible fully of results capable insured platform dynamic open system reimbursement shift quality due clinically is with full innovative paradigm savings open of clinical the is new automated no as and devices In sample delivering window current existing is collection throughput automated comparability We with with multiple be results. sample reagents processing It types. the the its Our market. is to high is and of open compatible only a platform possible now utilizing closed solution to very workflow. a platform and off double process It are. that costs platforms platform easily an what as can shift many in flexibility hour which access what currently typically our XXX
confidence. As development despite firmly XXXX cost it approved with forward year remains condition with products. is remain result a challenging and important and economically, more for an being allows a LDT moving excellent financial Clearly, while FDA's savings Enzo compatible
also is us. is this economic – companies providing high-value opportunity Enzo a known known in for While environment unique challenges and in to industry the growth are it and while a the other
will excited transition a about now our accomplishment company. the year We future. the for time. We call open next you be year believe questions. of and will for your thank We We the for very are extreme
